Immupharma Regulatory News (IMM)

RNS REACH

ImmuPharma to Present at

Rodman and Renshaw Annual Global Investment Conference, New York

Tuesday 11 September 2012

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the Rodman and Renshaw Annual Global Investment Conference on Tuesday 11 September 2012 at the Waldorf Astoria in New York City. Tracy Weimar, Vice President, Operations and Finance will present an overview of ImmuPharma at 16:55 PM Eastern Time.

If you would like to arrange a one to one meeting with ImmuPharma during this conference between 10-12 September, please do not hesitate to contact either Tracy Weimar or Lisa Baderoon, Head of Investor Relations.

Ends

For further information please contact:

Notes to Editors

ImmuPharma

ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The Company's most advanced drug candidate, LupuzorTM a potential blockbuster drug for Lupus, a chronic autoimmune disease has recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation. ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience. www.immupharma.com